HCA Healthcare, Inc.

HCA's valuation at 14.14x earnings looks remarkably compressed for a $110.8B healthcare operator, especially given the sector's typical multiples. The RSI of 30.9 signals oversold territory, suggesting recent selling pressure has pushed the stock into potential support levels. Trading below its 52-week high indicates the market has already punished HCA meaningfully from recent peaks. The combination of depressed momentum, an attractive P/E relative to healthcare services peers, and oversold technical conditions creates an intriguing asymmetry—either a legitimate repricing of earnings risks or a setup where mean reversion becomes feasible. The lack of high short interest data limits squeeze potential analysis, but the technical-valuation mismatch warrants close monitoring of upcoming earnings and hospital utilization trends.